Guillevin L, Jarrousse B, Lok C, Lhote F, Jais J P, Le Thi Huong Du D, Bussel A
Hôpital Avicenne, Service de Médecine Interne, Université Paris-Nord, Bobigny, France.
J Rheumatol. 1991 Apr;18(4):567-74.
We attempted to define the most effective treatment for polyarteritis nodosa and Churg-Strauss angiitis, with a prospective, randomized, multicenter trial of cyclophosphamide in conjunction with corticosteroids and plasma exchanges, compared to corticosteroids and plasma exchanges. A total of 71 patients who fulfilled clinical, histological and/or arteriographic diagnostic criteria were randomly designated to receive either prednisone and plasma exchanges (group A, n = 39) or cyclophosphamide, prednisone and plasma exchanges (group B, n = 32). The end points of the study were control of the disease (recovery and remission) and death. Upon study entry clinical and laboratory features did not differ in the 2 groups. Treatment was stopped in 19 patients because of ineffectiveness in 10 (9 in Group A) and side effects in 9 (8 in Group B). Initial control of the disease was similar in both groups. At 5 years, 27 patients had completely recovered and 14 patients were in clinical remission. The cyclophosphamide-prednisone-plasma exchange association was beneficial in preventing relapses during longterm followup. Nineteen deaths were reported during the followup period. There was no difference between the 10 year cumulative survival rates of the 2 groups (respectively, 72 and 75%). Thus, the association of cyclophosphamide with corticosteroids and plasma exchanges reduced the incidence of relapses and improved the quality of the clinical response to therapy.
我们试图确定结节性多动脉炎和变应性肉芽肿性血管炎的最有效治疗方法,进行了一项前瞻性、随机、多中心试验,比较环磷酰胺联合皮质类固醇及血浆置换与皮质类固醇及血浆置换治疗的效果。共有71例符合临床、组织学和/或血管造影诊断标准的患者被随机分为两组,一组接受泼尼松和血浆置换(A组,n = 39),另一组接受环磷酰胺、泼尼松和血浆置换(B组,n = 32)。研究的终点为疾病控制(康复和缓解)及死亡。研究开始时,两组的临床和实验室特征并无差异。19例患者因治疗无效(10例,A组9例)或出现副作用(9例,B组8例)而停止治疗。两组疾病的初始控制情况相似。5年后,27例患者完全康复,14例患者处于临床缓解期。在长期随访中,环磷酰胺-泼尼松-血浆置换联合治疗有助于预防复发。随访期间报告了19例死亡病例。两组的10年累积生存率无差异(分别为72%和75%)。因此,环磷酰胺与皮质类固醇及血浆置换联合使用可降低复发率,并改善治疗的临床反应质量。